European Medicines Agency
The European Medicines Agency (EMA) has established ‘eligibility criteria’ in order to make sure that it only establishes dialogue with the most suitable organisations that act in the interests of European patients, consumers and healthcare professionals. The European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) would like to engage in dialogue with the EMA and has provided the following information for the evaluation of eligibility.
As part of the evaluation for eligibility, ECTRIMS has provided the following financial information to be assessed by the parameters as set by the European Medicines Agency:
FUNDING Sources 2019:
The following companies / organisations provide funding to ECTRIMS:
- Alexion Pharmaceuticals Inc
- Almirall, S.A.
- Bayer AG
- Biogen International GmbH
- Celgene International
- CorTechs Labs
- F. Hoffmann-La Roche Ltd.
- HRA Healthcare Research & Analytics
- Janssen Research & Development
- jung diagnostics GmbH
- Medday Pharmaceuticals SA
- MS Brain Health
- MS Experience
- MSBase Registry (MSBase Foundation Ltd)
- Novartis Pharma AG
- Quantib BV
- Sanofi Genzyme
- Sydney Neuroimaging Analysis Centre
- Teva Pharmaceuticals Europe BV
- UK MS Register / MS Tissue Bank
- Ung med MS
- Viela Bio
- Wisepress Ltd
- Zero Gravity Skin
The highest contribution from a single company is less than 6.57% of the organisation’s total income.
The industry related income amounts to 37% of the overall organisations’s income.
The non-industry related income amounts to 63% of the overall organisations’s income.
Code of Conduct:
ECTRIMS operates within the established code of conduct or the European Medicines Agency.